▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Todd Campbell

tmfebcapital

@ebcapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent Articles by Todd Campbell

May 29, 2014 by Todd Campbell

Scorned Pfizer Should Forget AstraZeneca and Buy Celgene Instead

Pfizer's attempts to buy AstraZeneca have been rebuffed, shifting attention to other companies that could help expand Pfizer's product line, including Celgene.

May 24, 2014 by Todd Campbell

3 Breakthrough Drugs Yield 1 Instant Blockbuster

Roche (RHHBY), Johnson & Johnson (JNJ) and Gilead (GILD) each launched one drug in 2013 that was approved under the FDA's new breakthrough therapy designation. Here's what you need to know about their first quarter performance.

May 19, 2014 by Todd Campbell

3 Reasons to Buy Teva Pharmaceuticals

Teva (TEVA) faces a big hurdle once Copaxone loses patent protection, but only if Mylan (MYL) and Novartis (NVS) win FDA approval for their biosimilars. Here are three reasons investors should consider owning Teva.

May 19, 2014 by Todd Campbell

Is Now a Good Time to Buy Bristol Myers?

Investors knocked Bristol-Myers (BMY) down more than 5% on worries about lackluster results from a mid-stage study, but selling shares may not be the best choice.

May 19, 2014 by Todd Campbell

Pfizer's Other Big News

Pfizer (PFE) palbociclib may soon join drugs from Novartis (NVS) and AstraZeneca (AZN) in treating breast cancer.

May 18, 2014 by Todd Campbell

E-Cigarettes: Questions Remain for Lorillard, Altria, and Reynolds

Lorrilard (LO), Altria (MO), and Reynolds (RAI) are investing in e-cigarettes. Here's what you need to know about this fast-growing consumer trend.

May 18, 2014 by Todd Campbell

3 Companies Frightened by This Medicare Study

Rand has issued a report suggesting that CMS begin considering price. If it does, it could mean trouble for high-priced drugs from Gilead, Sanofi, and Celgene.

May 17, 2014 by Todd Campbell

1 Stock Putting A New Spin on an Old Marijuana Drug

Insys is falling on worries over its opioid painkiller Subsys, but it also has an intriguing new formulation of the THC drug Marinol in the works.

May 17, 2014 by Todd Campbell

Investing in a Good Night's Sleep

ResMed (RMD) and Philips Electronics (PHG) dominate the CPAP market for sleep apnea, but new products like Inspire's new neurostimulation system could threaten their leadership in the coming years.

May 17, 2014 by Todd Campbell

Why the Market Is Wrong About This Popular Marijuana Stock

GW Pharmaceuticals is a promising company working on important medical marijuana-based drugs for MS, cancer, and diabetes, but it's just too expensive to buy.

May 16, 2014 by Todd Campbell

3 Biotech Dividend Darlings for Your Portfolio

Here's what you need to know about Amgen (AMGN), Teva Pharmaceuticals (TEVA), and PDL Biopharma's (PDLI) healthy dividend pay-outs.

May 15, 2014 by Todd Campbell

Could Bristol-Myers End Up Acquiring Celldex?

Celldex (CLDX) began as a subidiary of Bristol-Myers (BMY) Medarex. Here's what you need to know about their collaboration.

May 15, 2014 by Todd Campbell

Kindred + Gentiva: Here's What You Need To Know

Kindred (KND) is offering to buy Gentiva (GTIV), but Gentiva isn't biting. Here's what you should know about the proposed deal.

May 14, 2014 by Todd Campbell

Alnylam: The Best Hepatitis B Play?

Alnylam (ALNY) has big plans for hepatitis B treatment, but Gilead's (GILD) program is far closer to market.

May 13, 2014 by Todd Campbell

What Was Behind Tesaro Inc.'s 21% Pop?

Tesaro and Opko's rolapitant successfully achieved primary and secondary endpoints in reducing chemotherapy-induced nausea and vomiting.

May 11, 2014 by Todd Campbell

Are Generic Drugs Boosting Rite Aid's Business?

Generic introductions should provide plenty of margin-friendly tailwinds for pharmacy chains Rite Aid, CVS, and Walgreen over the coming two years.

May 11, 2014 by Todd Campbell

Is Dendreon Back on Solid Ground?

Dendreon (DNDN) faces stiff competition from Johnson & Johnson (JNJ) and Medivation (MDVN), but a significant restructuring is lopping off costs in a bid to make the company profitable.

May 11, 2014 by Todd Campbell

3 Drugs Set to Become Blockbusters in 2014

Medivation (MDVN), Gilead (GILD) and Biogen (BIIB) all have new drugs likely to exceed the $1 billion annual sales mark this year.

May 11, 2014 by Todd Campbell

Is This The Next Billion-Dollar Biotech Idea?

Mylan, Novartis, and Hospira are among a slate of companies advancing biosimilars to market, potentially threatening tens of billions in branded sales of biologics.

May 11, 2014 by Todd Campbell

What You Need to Know About Medivation Inc.'s Results

Medivation (MDVN) and Astellas (ALPMY) saw U.S. sales growth slow this quarter, but growth overseas took off. Here's what could be in store for these stocks through the rest of the year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services